Document is current
Any future updates will be listed below
-
Authors
Lindén, Malin https://orcid.org/0000-0002-9055-2575
Andersson, Lisa
Albatrok, Heba
Canfjorden, Vilma
Jonasson, Emma
Grönqvist, Kajsa
Sjövall, Daniel
Jaako, Pekka
Crescitelli, Rossella
Fagman, Henrik
Åman, Pierre
Ståhlberg, Anders https://orcid.org/0000-0003-4243-0191
-
Funding
Funding for this research was provided by:
Cancerfonden (22-2080, 22-2470)
•the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (966318, 965065, 1006009)
Västra Götalandsregionen
Vetenskapsrådet (2021-01008, 2023-02239)
Barncancerfonden (2022-0030, D2025-0003)
Stiftelsen Assar Gabrielssons Fond
Johan Jansson Foundation
Stiftelserna Wilhelm och Martina Lundgrens
Eva Lidén foundation
Magnus Bergvalls Stiftelse
Anna-Lisa och Bror Björnssons Stiftelse
- License Information
-
More Information
Article History
Received: 18 March 2025
Accepted: 3 September 2025
First Online: 23 September 2025
Declarations
:
: Not applicable.
: Not applicable.
: AS is shareholder and board member of Tulebovaasta, and shareholder of Simsen Diagnostics and iScaff Pharma. R.C. has developed multiple extracellular vesicle-associated patents for putative clinical utilization. R.C. owns equity in Exocure Bioscience Inc.
